The difference between this story and the story we reviewed on the same topic by the New York Times can be seen even in the headlines. This one leads readers to believe that there is a risk in eating less salt. The New York Times, though, took the more cautious approach of saying, “Low-Salt Diet Ineffective, Study Finds. Disagreement Abounds.” We think that given the problems with this study, the more cautious approach was appropriate.
As with the harms, the benefits were not quantified.
There is no quantification of harms or benefits in this story. Instead we are told, “They found that systolic blood pressure (the top number) was slightly lower in those who excreted less sodium, but this didn’t translate into a lower risk of cardiovascular death — in fact, those with lower sodium excretion had an increased risk of cardiovascular death. The findings were consistent in participants younger and older than 60 years.” The New York Times story put the harms (and benefits) in absolute terms, showing both the small sample size of the number of people who died and the differences in the categories.
Unlike the New York Times story, this one did not evaluate the quality of the evidence. The story said, vaguely, “The research is already drawing fire from medical experts here. Ralph Sacco, president of the American Heart Association and chairman of neurology at the University of Miami, says this is only one study of a relatively young, mostly white population and blood pressure tends to rise with age and affect African-Americans disproportionately.” Again, this might lead most people in the United States to think that they are at risk when, in fact, there were other significant limitations to the study that were ignored.
The story did not engage in overt disease-mongering, but we do feel readers will be confused about whether they should be worried about their salt intake. There is so little information presented about the specifics of the study that many people might assume that they are eating too little salt.
The story does quote an independent expert but then turns around and cites a spokesman for the Salt Institute, a salt advocacy organization. Why should they be given a platform in this story? We thought that more weight should have been given to the independent analysis, as was done in the New York Times story. The Times, for example, sought out a well respected expert, Dr. Lawrence Appel.
(Addendum added May 6: It’s worth noting that the independent experts in this field, such as Dr. Appel and Dr. Sacks (who are also quoted in the Times story), are closely affiliated with NHLBI which funds much of the research on sodium. And as Gary Taubes posited many years ago in Science magazine, the NHLBI may not be a dispassionate arbiter of the evidence. (The full text of his story can be accessed at the National Association of Science Writers website: http://www.nasw.org/1999-science-society-awards.)
This criterion does not apply in this story.
This study is presented as just another study of equal weight with everything else that has been published on heart disease and salt. It should have been presented as an one study with significant flaws.
The story does not rely on a news release.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like